Symbiotec Pharmalab IPO GMP Today: GMP hints at 41% Listing

24 Aug 2026 , 11:20 AM

The Symbiotec Pharmalab IPO GMP is currently at ₹409 as of August 24, 2026, according to the latest available grey market data. With the IPO price fixed at ₹988 per share, the current GMP indicates an estimated listing price of ₹1,397, representing a potential listing gain of around 41.40% over the issue price.

The IPO opened for subscription today, August 24, with the latest subscription level standing at 0.10x as of 10:33 AM.

Symbiotec Pharmalab IPO GMP Trend

GMP Date	IPO Price	GMP	Estimated Listing Price	Estimated Gain
24-Aug-2026	₹988	₹409	₹1,397	41.40%
23-Aug-2026	₹988	₹409	₹1,397	41.40%
22-Aug-2026	₹988	₹410	₹1,398	41.50%
21-Aug-2026	₹988	₹345	₹1,333	34.92%
20-Aug-2026	₹988	₹300	₹1,288	30.36%
19-Aug-2026	₹988	₹220	₹1,208	22.27%

The GMP has increased significantly from ₹220 on August 19 to ₹409 on August 24. It touched a recent high of ₹410 on August 22 before marginally easing to ₹409.

At the current GMP of ₹409, the estimated listing price is calculated as:

₹988 (IPO price) + ₹409 (GMP) = ₹1,397

This implies an estimated premium of 41.40% over the IPO price.

What Does the Symbiotec Pharmalab IPO GMP Indicate?

The grey market premium provides an unofficial indication of market sentiment towards an IPO ahead of its listing. However, GMP is not an official indicator and can change based on market conditions, demand and investor sentiment.

Investors should consider the company’s fundamentals, IPO valuation, subscription figures and broader market conditions rather than relying solely on the GMP.

 

Disclaimer – The stock/s and indices mentioned in this article are discussed solely for informational and educational purposes. It should not be construed as investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research or consult a financial advisor before making any investment decisions. Investments in securities markets are subject to market risks. Read all the related documents carefully before investing.